Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $27.00 price target on Fate Therapeutics (NASDAQ: FATE) after the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE